...
首页> 外文期刊>HIV/AIDS: Research and Palliative Care >Dolutegravir/rilpivirine for the treatment of HIV-1 infection
【24h】

Dolutegravir/rilpivirine for the treatment of HIV-1 infection

机译:Dolutegravir / rilpivirine治疗HIV-1感染

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Much progress has been made in the development of antiretroviral therapies (ARTs) for HIV-1 infection. Beginning a little over a decade ago, single tablet combination regimens (STRs) became available, and subsequently, newer STR formulations with improved safety profiles have emerged. Recently, there is a growing interest in regimen simplification with the primary goal of further reducing long-term toxicities of ART and improving medication adherence. Dolutegravir/rilpivirine (DTG/RPV) was approved by the US Food and Drug Administration (FDA) as the first dual antiretroviral STR for the maintenance therapy of HIV-1 infection. Following an extensive review of all published papers on RPV and DTG, administered alone and in combination, extracted from databases including PubMed, Google scholar, and EMBASE, as well as drug package inserts and conference abstracts and proceedings, this review discusses the chemical properties and composition, pharmacodynamics and pharmacokinetic properties, clinical trial efficacy and safety data, as well as important drug–drug interactions associated with DTG/RPV. An expert opinion section discusses ideal candidates for DTG/RPV in the context of available but limited data and in comparison to currently available and emerging ART alternatives.
机译:在开发用于HIV-1感染的抗逆转录病毒疗法(ART)方面已经取得了很大进展。大约十年前开始,出现了单片组合疗法(STRs),随后出现了具有改善安全性的新型STR制剂。最近,人们对简化方案的兴趣日益浓厚,其主要目标是进一步降低ART的长期毒性并改善药物依从性。 Dolutegravir / rilpivirine(DTG / RPV)被美国食品和药物管理局(FDA)批准为首个用于HIV-1感染维持治疗的双重抗逆转录病毒STR。在广泛审查了有关RPV和DTG的所有已发表论文后,对它们进行了单独管理和组合管理,并从包括PubMed,Google Scholar和EMBASE在内的数据库中提取,以及药品说明书,会议摘要和会议记录,讨论了化学性质和组成,药效学和药代动力学特性,临床试验功效和安全性数据,以及与DTG / RPV相关的重要药物相互作用。专家意见部分在可用但有限的数据背景下,与当前可用的和新兴的ART替代方案相比,讨论了DTG / RPV的理想候选对象。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号